Match Document Document Title
10526642 DNA methylation in colorectal and breast cancer diagnostic methods  
The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm....
10526606 Targeting WSB1 and pVHL to treat cancer  
Materials and methods for treating cancer (e.g., by reducing metastasis) are provided herein. For example, materials and methods for treating cancer by targeting WSB1 and/or pVHL are provided.
10526412 Anti APRIL (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer  
An antibody or a fragment thereof directed against an epitope including or being constituted by at least six contiguous amino acids in the SEQ ID NO: 1 or a conformational epitope comprising or...
10526389 Peptides and combinations of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers  
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The...
10526388 Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells  
The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.
10526291 Potent dual BRD4-kinase inhibitors as cancer therapeutics  
Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects,...
10526290 Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy  
The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy.
10525139 Folate-conjugated molecules for delivery of toxic small molecule inhibitors to cancer cells and methods of use  
The invention relates to novel derivatives of thapsigargin that are chemically modified with a group that targets a cell surface-expressed receptor, and pharmaceutical preparations thereof. The...
10525118 Recombinant Mycobacterium as an immunotherapeutic agent for the treatment of cancer  
The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the...
10525104 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer  
The present invention provides methods for treating metastatic cancer comprising identifying subjects who will respond favorably to anti-VEGF therapy. According to certain aspects of the...
10525091 Use of parvovirus for eliminating cancer stem cells (CSCs)  
Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
10525079 Pharmaceutical composition for preventing or treating breast cancer including crystalline polymorph of tetraarsenic hexoxide, and method for producing same  
The present invention relates to a pharmaceutical composition for preventing or treating breast cancer which includes tetraarsenic hexoxide in which a crystalline polymorph a(As4O6-a), of...
10525074 Combination therapy for treating cancer  
The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of...
10525063 Methods of reducing mammographic breast density and/or breast cancer risk  
The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal,...
10525037 Compounds for treatment of cancer  
The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination...
10525031 Lipid furan, pyrrole, and thiophene compounds for treatment of cancer, neurological disorders, and fibrotic disorders  
Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective...
10525022 Pharmaceutical composition for treating cancer, containing lactate metal salt  
The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into...
10525021 Mitochondrial uncouplers for treatment of metabolic diseases and cancer  
2-hydroxy-benzoic anilide compounds and derivatives, compositions thereof, and methods for treating metabolic diseases and cancer through uncoupling mitochondria.
10521557 Systems and methods for providing dynamic, individualized digital therapeutics for cancer prevention, detection, treatment, and survivorship  
Methods, systems, and apparatus, including computer programs stored on a computer-readable storage medium, for providing dynamic, individualized digital therapeutics for cancer patients and cancer...
10519513 Cancer Biomarkers  
Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.
10519512 STK32C gene relevant to breast cancer and use thereof  
The present invention relates to the serine threonine kinase 32C (STK32C) gene relevant to breast cancer and a use thereof, and particularly, to a composition for the diagnosis, prevention, or...
10519506 Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer  
The present invention includes methods and biomarkers for diagnosing or detecting colorectal cancer metastasis in a human subject by comparing the Alu repeat methylation level in the biological...
10519505 Genomic signatures of metastasis in prostate cancer  
A method of determining the risk of metastasis of prostate cancer in a human subject who has or had prostate cancer is disclosed herein. The method is based on detecting in a prostate sample from...
10519245 Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer  
There is disclosed compositions and methods relating to or derived from anti-IGF1R antibodies. More specifically, there is disclosed fully human antibodies that bind IGF1R, IGF1R-binding fragments...
10519214 Methods and compositions for chimeric antigen receptor targeting cancer cells  
The present invention provides a chimeric antigen receptor (CAR) that recognizes B7-H3 (CD276), as well as methods of use in the treatment of diseases and disorders.
10519210 Multi-level specific targeting of cancer cells  
A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more...
10519197 Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer  
The proteasome inhibitors of this invention include peptide-based compounds with a short linear sequence of amino acids. An oxo or thio group is attached to the N-terminal amino acid. A...
10519167 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies  
A compound of formula Ia, Ib, Ic or Id: wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting...
10519152 Compounds and their use in treating cancer  
The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the...
10519113 Kinase inhibitor compounds, compositions, and methods of treating cancer  
The present invention relates to a compound having the structure of formula (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where X, Y, Z, R, R1, R2, R3, R4,...
10518109 Transformable charged particle beam path cancer therapy apparatus and method of use thereof  
The invention comprises a method and apparatus for determining a radiation beam treatment path to a tumor, comprising the steps of: (1) delivering charged particles from an accelerator, along a...
10517969 Methods and kits for diagnosis of cancer and prediction of therapeutic value  
A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent...
10517958 Compositions and methods for the treatment of platinum-drug resistant cancer  
VAR2CSA-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum...
10517948 Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy  
The present disclosure is directed to antibodies that bind to DC-HIL on the surface of myeloid-derived suppressor cells, and thus antagonize the T cell suppressor function of these cells, as well...
10517937 Immunotherapy for the treatment of cancer  
Methods for the treatment of cancer using double negative (DN) T cells are described. The DNTs may be used for the treatment of chemotherapy-resistant cancers such as recurring or relapsing acute...
10517875 Targeting DNA-PKcs and B7-H1 to treat cancer  
Materials and methods for treating potentially chemoresistant tumors (e.g., using DNA-PKcs inhibitors and anti-B7-H1 antibodies) are provided herein.
10517861 Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds  
Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g.,...
10517844 Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications  
In various embodiments a cancer treatment method is provided based on inhibition of proline catabolism. When combined with p53 restoration therapy and/or inhibition of glutaminase, the inhibition...
10517843 Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy  
Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
10513739 Methylation markers for diagnosing hepatocellular carcinoma and lung cancer  
Disclosed herein, in certain embodiments, are methods and kits for diagnosing a subject as having hepatocellular carcinoma (HCC) or lung cancer. In some instances, also described herein are...
10513737 Cancer diagnostics using non-coding transcripts  
Disclosed herein, in certain instances, are methods for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances,...
10512761 Methods for delivery of therapeutic materials to treat pancreatic cancer  
Disclosed is a localized method for treatment of cancer including the steps of providing a drug delivery catheter; navigating the catheter to the bile duct; and delivering a therapeutic agent into...
10512662 Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy  
The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent...
10512661 Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease  
A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an...
10512651 Inhibition of MK2 in the treatment of cancer  
The present invention relates to the discovery that MK2 is highly expressed in cancer tissue and the inhibition of MK2 using an MK2 inhibitor represents a viable approach to the treatment of...
10512648 Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake  
A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric...
10512641 Chloroquine induction par-4 and treatment of cancer  
Described herein are methods for treating cancer in a subject in need thereof by administering chloroquine, or a salt or prodrug thereof, optionally with another agent that promotes Par-4...
10512630 Compositions and methods for treating cancer  
Provided herein, inter alia, are compositions and methods useful for treating hyperproliferative diseases, including cancer and non-malignant hyperproliferative diseases.
10512618 Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast  
The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial...
10512604 Radiation sensitizer or anti-cancer chemotherapy sensitizer  
The present invention provides a novel radiosensitizer or anti-cancer chemotherapy sensitizer. In particular, the invention provides a radiosensitizer or anti-cancer chemotherapy sensitizer that...